TMG for Liver Health: Fatty Liver Trials and What They Show

Affiliate disclosure: Biohack Blueprint may earn a commission from qualifying DoNotAge purchases through our links.

TMG liver benefits are often described in terms of methylation, fat metabolism and “detox.” Betaine does participate in normal liver biology. Whether swallowing extra betaine treats fatty liver, reduces fibrosis or improves clinical outcomes is a separate question, and the human evidence does not establish those benefits.

The most useful way to read this literature is chronologically: an encouraging pilot, a more demanding placebo-controlled trial with a published correction, and newer exploratory work. The correction is essential to the interpretation.

Why betaine attracted interest in liver research

Betaine is involved in methyl-group metabolism and cellular osmotic functions. Experimental models connect it to lipid handling, oxidative stress and other pathways relevant to liver injury. Reviews explain why these mechanisms make it a candidate for investigation. [1] [2]

Mechanistic plausibility is the beginning of a treatment question. It cannot establish an effective human amount or show that a commercial capsule prevents liver disease.

The early pilot was encouraging but small

A 2001 pilot enrolled ten people with nonalcoholic steatohepatitis, now commonly discussed within the MASH terminology. Seven completed one year of betaine treatment. Liver enzymes and biopsy measures improved in several participants. [3]

Without a randomized placebo comparison, the pilot could not separate treatment effects from changes in behavior, natural variability, selection of completers or other influences. Its small size made it a reason for a better trial, rather than a definitive treatment result.

The placebo-controlled trial and its correction

The later trial randomized 55 patients with biopsy-confirmed NASH to betaine at 20 grams daily or placebo for 12 months. Thirty-five completed treatment and 34 had repeat biopsies. The large difference between enrollment and biopsy follow-up matters when assessing certainty. [4]

The corrected conclusion states that betaine did not improve hepatic steatosis compared with placebo, although it might have limited worsening. Fibrosis and overall activity scores did not improve. The correction is linked on the Data Center study page and through the publisher’s correction notice.

It would be misleading to quote the original optimistic conclusion without the correction, or to turn a possible difference in worsening into proof of disease reversal. The trial also used an amount far above a typical retail capsule serving.

What do the newer MASLD pilot studies add?

A recent report describes 70 participants across three cohorts. It examined 4 versus 8 grams daily in one cohort, plus separate 1- and 2-gram cohorts. Liver enzymes and several injury markers decreased at some amounts, while the 1-gram cohort did not show the same pattern. [5]

The design is important: an active-dose comparison and uncontrolled cohorts do not supply the same efficacy test as a placebo-controlled treatment comparison. Baseline-to-follow-up improvement can have explanations other than the assigned supplement. Mild transient gastrointestinal symptoms were also reported.

Evidence	What it contributes	Main limit
Early ten-person pilot	Preliminary enzyme and biopsy observations	Small, uncontrolled and only seven one-year completers
Year-long randomized trial	Direct placebo comparison	Attrition; corrected conclusion does not establish improved steatosis
Recent dose-cohort pilots	Signals in enzymes and injury markers	No placebo comparison establishing a treatment effect

Read the newer liver pilot by cohort and duration

The newer MASLD report is not one large placebo-controlled trial of a single amount. It describes 70 participants across cohorts of 44, 10 and 16. The 44-person cohort compared 4 and 8 g/day over 12 weeks; the smaller cohorts examined 1 or 2 g/day over 24 weeks. Reported improvements in ALT and some injury markers at 2, 4 or 8 g/day were not matched by the same pattern at 1 g/day. ^[5]

Pooling those descriptions into “70 people proved TMG reverses fatty liver” would erase the study design. An active-dose comparison cannot establish what would have happened with placebo, and an uncontrolled cohort cannot separate a supplement effect from other changes over time. Approximately 35% reported mild transient gastrointestinal symptoms; that figure belongs to these protocols and participants.

Nor can the observed dose pattern define a minimum effective self-treatment dose. The cohorts differed in size and duration, and a small uncontrolled result is not a dose-finding trial that establishes an optimal regimen for all adults with liver disease.

ALT, liver fat and fibrosis are different endpoints

Outcome	What a study can measure	What should not be assumed
Liver enzymes such as ALT	A change in a blood marker of injury	That fibrosis has reversed or clinical complications will be prevented
Steatosis	Liver-fat measures by a specified method	That every enzyme improvement means less fat
Inflammatory activity or fibrosis	Specified biopsy or validated assessment outcomes	That a normal metabolic role establishes treatment efficacy
Clinical outcomes	Disease progression, complications or other patient-relevant events	That an animal mechanism or short pilot demonstrates long-term benefit

Combination formulas are a different intervention

A randomized pilot in adults with obesity and metabolic syndrome tested a nutrient cocktail containing betaine, choline, folate, omega-3 fats and B12. Some liver-related measurements improved. That result belongs to the whole cocktail; it cannot identify TMG’s contribution. [6]

Other older liver research used betaine glucuronate with additional compounds. This is also different from isolated betaine anhydrous. [7] Similarly, a hepatitis C pilot combined betaine with SAMe and interferon/ribavirin. It does not establish a modern standalone TMG treatment. [8]

Why “liver detox” is too vague to judge

A useful study specifies what it measured: ALT, imaging-based fat estimates, liver stiffness, biopsy features, fibrosis progression or clinical events. “Detox” can blur those distinct outcomes into an undefined promise.

A lower enzyme concentration does not automatically mean less fibrosis, and a favorable animal pathway does not establish a human clinical outcome. If a product claim cannot identify the outcome and the human evidence, the wording is more specific than the data justify.

Does it protect the liver from alcohol?

Animal experiments can help investigate alcohol-related pathways, but they cannot establish that TMG makes drinking safer. Historical reports and uncontrolled case observations also cannot provide that assurance. Using a supplement to offset alcohol exposure is not a benefit demonstrated by the human trials reviewed here.

Questions to take to a liver-care appointment

Ask what is being treated and how the response will be assessed. “Fatty liver,” elevated enzymes, alcohol-related injury and an inherited metabolic disorder are not interchangeable diagnoses. Current MASLD/MASH terminology also does not turn all older betaine studies into trials of the same modern patient population.

Useful questions include whether the cause of the abnormal findings has been assessed, how fibrosis risk is being evaluated, which medicines and supplements should be disclosed, and which changes in the broader care plan have evidence for the individual situation. Bring the exact product label if you are considering TMG.

The 20 g/day year-long NASH protocol should not become a home dosing plan. In 500 mg capsule units it would represent 40 capsules a day—a calculation illustrating the large exposure difference, not a suggestion to use it. That trial’s corrected efficacy conclusion is also a reason to resist assuming that a larger amount must produce a better outcome. ^[4]

A capsule can be convenient and clearly labeled while the treatment claim remains unestablished. Our product review scores those product characteristics separately. No retailer’s star rating can supply a missing placebo-controlled clinical result.

Do not let a pilot erase the placebo-controlled result

The older randomized fatty-liver trial’s corrected interpretation was neutral for improvement in hepatic steatosis versus placebo, with a possible limitation of worsening. Fibrosis and overall activity scores did not improve. This is important context for later uncontrolled or dose-comparison enzyme signals. ^[4]

The 2026 pilot programme reported lower enzymes and selected injury markers at some tested amounts, alongside gastrointestinal events. Without treating its design as equivalent to a large blinded placebo comparison, it provides a reason for further research rather than proof that a wellness capsule reverses MASLD or MASH. ^[9]

Enzymes, MRI or biopsy fat, inflammation, fibrosis and clinical complications are different outcomes. A falling ALT can be encouraging without establishing fibrosis reversal or fewer liver events. Interpretation also depends on weight change, other treatment and adherence. Keep any supplement decision within the care of the diagnosed liver condition, rather than using “detox” as a substitute for a measured endpoint.

What this means for a supplement decision

Do not use TMG as a substitute for assessment or treatment of elevated liver enzymes or diagnosed MASLD/MASH. The cause, fibrosis risk and broader metabolic picture need appropriate care. Doses used in experimental liver protocols should not be copied into a self-directed routine.

The dose guide separates research amounts from labels, and the safety guide covers tolerability and lipids. Our DoNotAge Pure TMG review assesses a capsule product for an appropriate user; its 5/5 editorial score is not a claim that the product treats liver disease.

Sources and next steps

Browse the complete 415-publication TMG Data Center for the original studies, methods, disclosures and limitations. The numbered references below identify the sources used for this article; the full library also retains supporting and null evidence.

Continue by question: TMG Supplement: Benefits, Dosage, Safety and Research · TMG Dosage Guide: Study Doses and Capsule Calculations · TMG Side Effects: Cholesterol, Digestion and Safety · TMG for Homocysteine: Dose, Results and Limitations.

Our recommended TMG product

DoNotAge Pure TMG — 5/5 editorial rating

Our first choice for a straightforward single-active capsule: 500 mg TMG per capsule, a vegan capsule and 60 or 366 capsules. The score assesses the formula, label clarity and practical product choice; clinical evidence is judged separately.

Read the full evidence-led review · View at DoNotAge. Use BB10 for 10% off eligible standalone products; confirm current checkout terms.

Affiliate disclosure: Biohack Blueprint may earn a commission from qualifying purchases. This is a desk-based editorial recommendation, not an independent batch assay or a promise of a health outcome.